We have developed an anti-IgE vaccine for the treatment of allergic asthma and rhinitis comprising two separate but admixed human IgE peptide Qb-VLP conjugates (Qb-Y and Qb-P) as antigen and aluminum hydroxide as adjuvant. Here, IGHE is linked to allergic asthma.